leflunomide has been researched along with Kidney Failure, Chronic in 6 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We repeatedly measured teriflunomide (A77-1726), the active metabolite of leflunomide, during standard hemodialysis sessions and calculated teriflunomide clearances in five patients with rheumatoid arthritis (RA) and end-stage renal disease." | 7.79 | Leflunomide in dialysis patients with rheumatoid arthritis--a pharmacokinetic study. ( Bergner, R; Löffler, C; Peters, L; Schmitt, V, 2013) |
| " We repeatedly measured teriflunomide (A77-1726), the active metabolite of leflunomide, during standard hemodialysis sessions and calculated teriflunomide clearances in five patients with rheumatoid arthritis (RA) and end-stage renal disease." | 3.79 | Leflunomide in dialysis patients with rheumatoid arthritis--a pharmacokinetic study. ( Bergner, R; Löffler, C; Peters, L; Schmitt, V, 2013) |
| "In patients with IgA nephropathy and proteinuria > 1 g/day, steroid therapy given for generally two to four months with a tapering course probably prevents the progression to ESKD compared to placebo or standard care (8 studies; 741 participants: RR 0." | 2.66 | Immunosuppressive agents for treating IgA nephropathy. ( Craig, JC; Molony, DA; Natale, P; Palmer, SC; Ruospo, M; Saglimbene, VM; Samuels, JA; Schena, FP; Strippoli, GF; Vecchio, M, 2020) |
| " The dosage was increased to 20 mg/day after 3 months." | 1.39 | Leflunomide for inflammatory arthritis in end-stage renal disease on peritoneal dialysis: a pharmacokinetic and pharmacogenetic study. ( Ahern, MJ; Barbara, JA; Russo, PA; Shanahan, EM; Smith, MD; Wiese, MD, 2013) |
| "Prior to admission, she had been treated for rheumatoid arthritis with methotrexate 7." | 1.31 | Effect of hemodialysis on leflunomide plasma concentrations. ( Beaman, JM; Hackett, LP; Illett, KF; Luxton, G, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Natale, P | 1 |
| Palmer, SC | 1 |
| Ruospo, M | 1 |
| Saglimbene, VM | 1 |
| Craig, JC | 1 |
| Vecchio, M | 1 |
| Samuels, JA | 1 |
| Molony, DA | 1 |
| Schena, FP | 1 |
| Strippoli, GF | 1 |
| Russo, PA | 1 |
| Wiese, MD | 1 |
| Smith, MD | 1 |
| Ahern, MJ | 1 |
| Barbara, JA | 1 |
| Shanahan, EM | 1 |
| Yang, D | 1 |
| Keys, B | 1 |
| J Conti, D | 1 |
| Foulke, L | 1 |
| Stellrecht, K | 1 |
| Cook, L | 1 |
| Lopez-Soler, RI | 1 |
| Araya, CE | 1 |
| Garin, EH | 1 |
| Neiberger, RE | 1 |
| Dharnidharka, VR | 1 |
| Bergner, R | 1 |
| Peters, L | 1 |
| Schmitt, V | 1 |
| Löffler, C | 1 |
| Beaman, JM | 1 |
| Hackett, LP | 1 |
| Luxton, G | 1 |
| Illett, KF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| BK Viremia and BK Virus Nephropathy Post Kidney Transplant Comparison of New Practices With Traditional Approach: A Combined Retrospective Chart Review and Prospective Observational Study[NCT02758288] | 0 participants (Actual) | Observational | 2015-09-30 | Withdrawn | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for leflunomide and Kidney Failure, Chronic
| Article | Year |
|---|---|
Immunosuppressive agents for treating IgA nephropathy.
Topics: Adult; Calcineurin Inhibitors; Cause of Death; Child; Confidence Intervals; Creatinine; Drug Adminis | 2020 |
JC polyomavirus nephropathy, a rare cause of transplant dysfunction: Case report and review of literature.
Topics: Biopsy; BK Virus; Creatinine; Graft Rejection; Humans; Immunoglobulins, Intravenous; Immunosuppressi | 2017 |
4 other studies available for leflunomide and Kidney Failure, Chronic
| Article | Year |
|---|---|
Leflunomide for inflammatory arthritis in end-stage renal disease on peritoneal dialysis: a pharmacokinetic and pharmacogenetic study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Psoriatic; Aryl Hydr | 2013 |
Leflunomide therapy for BK virus allograft nephropathy in pediatric and young adult kidney transplant recipients.
Topics: Antiviral Agents; BK Virus; Child; DNA, Viral; Dose-Response Relationship, Drug; Enzyme Inhibitors; | 2010 |
Leflunomide in dialysis patients with rheumatoid arthritis--a pharmacokinetic study.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Crotonates; Female; Hum | 2013 |
Effect of hemodialysis on leflunomide plasma concentrations.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Biotrans | 2002 |